News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlycoMimetics, Inc. Completes Enrollment in Phase 2 Sickle Cell Disease Study With Lead Drug Candidate GMI-1070


1/17/2013 9:22:19 AM

GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company researching a new class of glycobiology-based therapies for a broad range of diseases, today announced that it has completed enrolling patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate. This randomized, double-blinded study examined the efficacy, safety and pharmacokinetics of GMI-1070 in hospitalized sickle cell disease patients experiencing vaso-occlusive crisis (VOC). Since the trial was initiated GlycoMimetics has enrolled 76 patients ages 12 to 65 at 22 trial sites in the United States and Canada. The company anticipates reporting topline data in the second quarter of 2013.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES